Wave Life Sciences Ltd. - Ordinary Shares (WVE)

On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.

The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which evaluates WVE-007—an investigational RNA interference (RNAi) therapy targeting the INHBE gene—aims to revolutionize obesity treatment by focusing

Wave Life Sciences (WVE) Earnings Call Transcript

This biotech innovator in genetic medicines reported significant insider selling, as disclosed in recent SEC filings.

In today's session, these stocks are experiencing unusual volume.

There's nothing like a nearly 150% price gain to garner the attention of investors and analysts.

Discover the stocks with unexpected trading volume in today's session on the US markets.

The company's investigational GLP-1 treatment performed admirably well in a phase 2b study.

We have an emerging new entrant in the increasingly crowded weight loss drug space.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for

Wave Life Sciences (WVE) Earnings Transcript